Reata Pharmaceuticals is a clinical-stage biopharmaceutical company focused on identifying, developing, and commercializing therapies. Co. focuses on therapeutics for the treatment of diseases with few or no approved therapies. Co.'s main programs are in rare forms of chronic kidney disease (CKD) and a rare neurological disease. Co.'s primary product candidates include bardoxolone methyl (bardoxolone) in patients with CKD caused by Alport syndrome and omaveloxolone in patients with a neurological disorder called Friedreich's ataxia. Both bardoxolone and omaveloxolone activate the transcription factor Nrf2 to normalize mitochondrial function, restore redox balance, and resolve inflammation. We show 30 historical shares outstanding datapoints in our RETA shares outstanding history coverage, used to compute RETA market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing RETA market cap history over the course of time is important for investors
interested in comparing RETA's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of RETA versus a peer is one thing; comparing
RETA market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like RETA can fluctuate over the course of history.
With this page we aim to empower investors researching RETA by allowing them to research the RETA market cap history. |
Free RETA Email Alerts:
Video: The Importance of Market Cap
